These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10602703)

  • 1. A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.
    Belliotti TR; Wustrow DJ; Brink WA; Zoski KT; Shih YH; Whetzel SZ; Georgic LM; Corbin AE; Akunne HC; Heffner TG; Pugsley TA; Wise LD
    J Med Chem; 1999 Dec; 42(25):5181-7. PubMed ID: 10602703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists.
    Pugsley TA; Shih YH; Whetzel SZ; Zoski K; Van Leeuwen D; Akunne H; Mackenzie R; Heffner TG; Wustrow D; Wise LD
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):219-26. PubMed ID: 11817497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of potent and selective dopamine D4 receptor antagonists.
    Faraci WS; Zorn SH; Sanner MA; Fliri A
    Curr Opin Chem Biol; 1998 Aug; 2(4):535-40. PubMed ID: 9736928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.
    Kesten SR; Heffner TG; Johnson SJ; Pugsley TA; Wright JL; Wise LD
    J Med Chem; 1999 Sep; 42(18):3718-25. PubMed ID: 10479303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Doubleday R; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Dec; 40(25):4026-9. PubMed ID: 9406594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, characterization and biological evaluation of a novel (R)-4,4-difluoropiperidine scaffold as dopamine receptor 4 (D
    Jeffries DE; Witt JO; McCollum AL; Temple KJ; Hurtado MA; Harp JM; Blobaum AL; Lindsley CW; Hopkins CR
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5757-5764. PubMed ID: 28327307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
    Macdonald GJ; Branch CL; Hadley MS; Johnson CN; Nash DJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Winborn KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Watson JM; Wood M; Parker SG; Ashby CR
    J Med Chem; 2003 Nov; 46(23):4952-64. PubMed ID: 14584946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
    TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
    J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
    [No Abstract]   [Full Text] [Related]  

  • 9. trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents.
    Zhang X; Hodgetts K; Rachwal S; Zhao H; Wasley JW; Craven K; Brodbeck R; Kieltyka A; Hoffman D; Bacolod MD; Girard B; Tran J; Thurkauf A
    J Med Chem; 2000 Oct; 43(21):3923-32. PubMed ID: 11052797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.
    Bøgesø KP; Arnt J; Frederiksen K; Hansen HO; Hyttel J; Pedersen H
    J Med Chem; 1995 Oct; 38(22):4380-92. PubMed ID: 7473566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist.
    Bristow LJ; Kramer MS; Kulagowski J; Patel S; Ragan CI; Seabrook GR
    Trends Pharmacol Sci; 1997 Jun; 18(6):186-8. PubMed ID: 9226994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.
    Sanner MA; Chappie TA; Dunaiskis AR; Fliri AF; Desai KA; Zorn SH; Jackson ER; Johnson CG; Morrone JM; Seymour PA; Majchrzak MJ; Faraci WS; Collins JL; Duignan DB; Prete Di CC; Lee JS; Trozzi A
    Bioorg Med Chem Lett; 1998 Apr; 8(7):725-30. PubMed ID: 9871530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.
    Campiani G; Butini S; Gemma S; Nacci V; Fattorusso C; Catalanotti B; Giorgi G; Cagnotto A; Goegan M; Mennini T; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2002 Jan; 45(2):344-59. PubMed ID: 11784139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
    J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release.
    Broderick PA; Piercey MF
    J Neural Transm (Vienna); 1998; 105(6-7):749-67. PubMed ID: 9826116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.